ATG16L1 and Sepsis: Furthermore, the expression levels of ATG5 and ATG16L1 in the 28-day non-surviving patients with sepsis were significantly decreased compared to the 28-day surviving patients, suggesting significant roles of ATG5 and ATG16L1 in the progression and outcome of sepsis, which may have potentially important therapeutic implications of sepsis and other inflammation-related disease.